Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Prostate Cancer Devices Market $2.6 Billion by 2027

The global market for prostate cancer devices anticipated to cross $2.6 billion by 2027, growing at a CAGR of 10.7% over the forecast period, driven by increasing demand for novel diagnostic tests and noninvasive treatment products worldwide.

  • Newly improved technologies and liquid biopsy tests in prostate cancer diagnostics are likely to prevent unnecessary biopsies, and replace less-than reliable prostate-specific antigen (PSA) tests.
    • Diagnosis is primarily based on prostate-specific antigen (PSA) testing, and transrectal ultrasound-guided (TRUS) prostate tissue biopsies, although PSA testing for screening remains controversial. 
    • Similarly, several noninvasive prostate cancer treatment products such as robotic-assisted laparoscopic prostatectomy, brachytherapy devices, high-intensity focused ultrasound devices and cryoablation devices, and novel hydrogel spacers are likely to boost the market growth.
Global Prostate Cancer Devices Market

Prostate cancer (PC) is the most common cancer among men worldwide, where approximately 60% of cases are diagnosed in men over 65. Based on GLOBOCAN estimates, 1,276,106 new cases of prostate cancer were reported worldwide in 2018, with higher prevalence in the developed countries.

  • The differences in the incidence rates worldwide reflect differences in the use of diagnostic testing. The incidence and mortality of prostate cancer worldwide correlate with increasing age with the average age at the time of diagnosis being 66 years. 

The global prostate cancer devices market research report provides market size (Revenue $million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027).

The global market for prostate cancer devices segmented by product [diagnostic products (biopsy guidance systems, fusion biopsy systems and software, molecular diagnostics and liquid biopsy products)], treatment products [minimally invasive surgery (robotic-assisted laparoscopic prostatectomy, radiation therapy (external beam radiation therapy, brachytherapy systems, hydrogel spacers), ablation systems (cryoablation, high-intensity focused ultrasound, irreversible electroporation)], end user (hospital laboratories, diagnostic laboratories, research institutes), and geography. 

  • Improved risk classification methods, imaging techniques, and biomarkers have improved the ability to provide prognostic information to patients with prostate cancer.
    • For the treatment of prostate cancer, monitoring for disease progression followed by local therapy is an accepted strategy for some men. Surgery and radiation techniques continue to evolve as treatment-related adverse effects are better defined.
      • Advances in the diagnosis and treatment of prostate cancer have improved the ability to stratify patients by risk and allowed clinicians to recommend therapy based on cancer prognosis and patient preference. 
  • Based on the products, the prostate cancer treatment devices segment accounted for the largest share of the total market, approaching the fastest double-digit market growth during the next few years.
    • Among these devices, the robotic-assisted laparoscopic prostatectomy (RALP) products segment dominated the global market, followed by the brachytherapy systems segment.
      • Robot-assisted systems have been introduced in an attempt to reduce the difficulty involved in performing complex laparoscopic procedures.
        • Radical prostatectomy is a common frontline treatment, through an open, laparoscopic or robotic-assisted laparoscopic approach. Technical modifications have expanded beyond open surgical approaches to include laparoscopic radical prostatectomy (LRP) and RALP.
        • These new-generation techniques aim at reducing the risk of prostate cancer-specific mortality, while minimizing treatment-related morbidity and maintaining patient quality of life.
        • The robotic-assisted prostatectomy has gained remarkable worldwide distribution and has become a standard procedure for localized prostate cancer as a new ‘gold standard’.
          • It has been suggested that RALP facilitates a simplified version of the learning process, allowing quicker reduction in operative time compared to LRP.
            • Radical prostatectomy offers the greatest potential for a definitive cure for localized prostate cancer and a significant improvement in overall survival, cancer-specific survival and the development of distant metastases. 
              • There are also proven advantages in reduced blood loss and shorter recovery time. 
  • The prostate cancer diagnostic devices segment expected to demonstrate double-digit market growth during the forecast period.
    • Out of these products, the biopsy guidance systems segment led the global prostate cancer diagnostic devices market.
      • Patient selection for prostate biopsy is complex and is influenced by emerging use of prebiopsy imaging. Recent advances in imaging technology including multi-parametric MRI (mpMRI) have enabled non-invasive assessment of the prostate for suspicious lesions have lead to improvements in the early detection of prostate cancer. 
        • Magnetic resonance imaging (MRI) guidance improves the accuracy of prostate biopsy for the detection of clinically significant prostate cancer.
        • There are several methods currently in use for targeted prostate biopsy: direct MRI-guided (in-bore) biopsy, cognitive fusion biopsy and MRI–TRUS fusion biopsy.
          • The MRI–guided biopsy has been shown to help characterize pathologic findings more accurately than transrectal ultrasonography-guided (TRUS) biopsy, leading to improved detection of high-risk disease.

The global market for prostate cancer products research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • Prostate cancer is one of the most widespread tumors affecting the urinary system and the fifth-leading cause from cancer death in men worldwide.
    • In the US, the estimated new cases for year 2019 were 174,650 with a number of estimated deaths of 31,620, ranking just second among malignant tumors in men.
  • Prostate cancer is a prominent form of cancer diagnosed in men living in developed countries, for which radical prostatectomy is a common frontline treatment.

Moreover, the global prostate cancer devices market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major companies operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for in-vitro based molecular diagnostics and liquid biopsy testing devices for prostate cancer and profiled in this report include Eigen, Exosome Diagnostics, Inc., Hitachi Medical Systems Ltd., Hologic, Inc., Koelis SAS, MDxHealth SA, Philips Healthcare (InVivo Corporation), and Precision Medicine Group (ApoCell).

Major players operating in the global market for minimally invasive whole-prostate and focal treatment devices for prostate cancer and profiled in this report include Avateramedical N.V., Boston Scientific Corporation, CMR Surgical Ltd., Eckert & Ziegler Bebig GmbH, EDAP TMS S.A., Elekta AB, Intuitive Surgical, Inc., Medtronic plc , Meere Company, Profound Medical Corporation, Siemens Healthineers AG (Varian Medical Systems, Inc.), SonaCare Medical LLC, and TransEnterix, Inc.

  • Product / Device
    • Diagnostic Products
      • Biopsy Guidance Systems
      • Fusion Biopsy Systems and Software
      • Molecular Diagnostics and Liquid Biopsy Products
    • Treatment Products
      • Minimally Invasive Surgery
        • Robotic-assisted Laparoscopic Prostatectomy (RALP)
      • Radiation Therapy
        • External Beam Radiation Therapy (EBRT)
        • Brachytherapy Systems
        • Hydrogel Spacers
      • Ablation Systems
        • Cryoablation
        • High-intensity Focused Ultrasound (HIFU)
        • Irreversible Electroporation (IRE)
  • End User
    • Hospital Laboratories
    • Diagnostic Laboratories
    • Research Institutes
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Molecular Diagnostics and Liquid Biopsy Testing
      • Eigen
      • Exosome Diagnostics, Inc.
      • Hitachi Medical Systems/Hitachi Ltd.
      • Hologic, Inc.
      • Koelis SAS
      • MDxHealth SA
      • Philips Healthcare/Philips Medical Systems International BV (InVivo Corporation)
      • Precision for Medicine/Precision Medicine Group (ApoCell)
    • Minimally Invasive Treatments
      • Avateramedical N.V.
      • Boston Scientific Corporation
      • CMR Surgical Ltd.
      • Eckert & Ziegler Bebig GmbH
      • EDAP TMS S.A.
      • Elekta AB
      • Intuitive Surgical, Inc.
      • Medtronic plc
      • Meere Company
      • Profound Medical Corporation
      • Siemens Healthineers AG (Varian Medical Systems, Inc.)
      • SonaCare Medical LLC
      • TransEnterix, Inc.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]